NCT04025541Recruiting
Analysis of Circulating Tumor Markers in Blood
Source: ClinicalTrials.gov · Last updated 2 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 992 (estimated)
- First submitted
- 5 Jun 2019
- Start date
- 29 May 2018
- Primary completion date
- 29 May 2026
- Lead sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
- Diseases
- Lung cancer, Colorectal cancer, Sarcoma
- NCT number
- NCT04025541
What you commit to
- Study type: Interventional
- Planned participants: 992
- From 29 May 2018 to the primary completion date, 29 May 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Private persons of freedom or under guardianship,
- Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
- Pregnant woman and/or breast-feeding,
- Unaffiliated patient to Social Protection System,
Who the study is looking for
- Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
- Man or woman ≥ 18 years,
- Obtaining of the informed consent signed before any procedure of specific preselection on approval.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle Coordinator of this site? Confirm its status | Montpellier | France | Recruiting |
| ICM Coordinator of this site? Confirm its status | Montpellier | France | Recruiting |
Related publications
- Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib.Breast Cancer Res Treat · 2026 · PMID 42521839
- Liquid biopsy reveals the immune status and protein profiles linked to CTC burden and clinical outcomes in metastatic breast cancer.J Exp Clin Cancer Res · 2026 · PMID 42001180
This page is information, not medical advice. Discuss any trial with your doctor.